SHARE
COPY LINK

I

Denmark close to rolling out coronavirus immunity tests: SSI

The Danish health agency SSI hopes to soon approve coronavirus antibody tests which will show whether those who suspect they've had the disease are immune and can rejoin the workforce.

Denmark close to rolling out coronavirus immunity tests: SSI
An antibody test developed by the Dutch company Sensitest. Photo: Robin Utrecht/AFP/Ritzau Scanpix
“We're not there right now, but we're close,” Anders Fomsgaard, the agency's head doctor, told the Politiken newspaper. “I dare not set a date for when the first antibody tests can come out, but my clear expectation is that it will happen before the epidemic culminates.”
 
Karen Angeliki Krogfelt, professor of medical microbiology at Roskilde University, is working with Statens Serum Institute (SSI) to check the accuracy of the Chinese-made finger-prick blood tests, to determine if they can be used by the Danish authorities. 
 
These so-called 'serologic tests' check for the antibodies produced by the body to defend against the coronavirus virus, rather than testing whether someone is currently infected. 
 
“When people have a high antibody level, they have a very hard time getting infected again for a period of up to two years,” Krogfelt told the newspaper. “They can then be sent back to work without much risk of them becoming infected or spreading the infection to others, as they are now more resilient.” 
 
Knut Borch-Johnsen, Deputy Director at Holbæk hospital, said that such tests would be invaluable. 
 
“Today, I have to send staff home even if they have very mild symptoms because it might be coronavirus. If we knew they were immune, then some of them could stay at work,” he told the newspaper. 
 
The SSI project is being mirrored by governments across the world.
 
On Monday, Deborah Birx from the White House Coronavirus Task Force said the the US Food and Drug Administration (FDA) hoped to approve a test within weeks, while the UK has already purchased 3.5m tests, and hopes to send them out to people's homes within weeks. 
 

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.

COVID-19

Public Health Agency recommends two Covid doses next year for elderly

Sweden's Public Health Agency is recommending that those above the age of 80 should receive two doses of a Covid-19 vaccine a year, once in the spring and once in the autumn, as it shifts towards a longer-term strategy for the virus.

Public Health Agency recommends two Covid doses next year for elderly

In a new recommendation, the agency said that those living in elderly care centres, and those above the age of 80 should from March 1st receive two vaccinations a year, with a six month gap between doses. 

“Elderly people develop a somewhat worse immune defence after vaccination and immunity wanes faster than among young and healthy people,” the agency said. “That means that elderly people have a greater need of booster doses than younger ones. The Swedish Public Health Agency considers, based on the current knowledge, that it will be important even going into the future to have booster doses for the elderly and people in risk groups.” 

READ ALSO: 

People between the ages of 65 and 79 years old and young people with risk factors, such as obesity, diabetes, poor kidney function or high blood pressure, are recommended to take one additional dose per year.

The new vaccination recommendation, which will start to apply from March 1st next year, is only for 2023, Johanna Rubin, the investigator in the agency’s vaccination programme unit, explained. 

She said too much was still unclear about how long protection from vaccination lasted to institute a permanent programme.

“This recommendation applies to 2023. There is not really an abundance of data on how long protection lasts after a booster dose, of course, but this is what we can say for now,” she told the TT newswire. 

It was likely, however, that elderly people would end up being given an annual dose to protect them from any new variants, as has long been the case with influenza.

SHOW COMMENTS